Abstract
Background
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive tumor with a poor prognosis, despite the emergence of chemotherapies, unmet medical needs still exist for patients with metastatic PDAC (mPDAC). Surufatinib is a small-molecule tyrosine kinase inhibitor targets vascular endothelial growth factor (VEGFR) 1, 2, 3, fibroblast growth factor receptor 1 (FGFR1), and colony stimulating factor 1 receptor (CSF-1R). It was approved in China for patients with pancreatic and ex-pancreatic neuroendocrine tumors (NETs) based on Phase III trials: SANET-p and SANET-ep.
Method
We conducted a real world retrospective study of mPDAC patients who received the surufatinib between July 2022 and July 2023 at Zhejiang Cancer Hospital. In addition, patients who received first line chemotherapy at the same period were analyzed as comparison.
Result
As of November 30th 2023, 20 eligible patients were identified. The median progression-free survival (mPFS) of patients who received surufatinib treatment was 5.27 months (95% CI, 2.55–7.98). For fist line treatment, 9 patients received surufatinib combined with immune checkpoint inhibitors (ICIs) and the mPFS was 7.5 months (95% CI, 3.14–11.85), compared with an mPFS of 5.43 months (95% CI, 3.89–6.96) for 52 mPDAC patients received chemotherapy at the same period. Grade 3 or above Treatment Related Adverse Event (TRAE) were neutrophil count decreased (10%), and white blood cell count decreased (5%).
Conclusion
The anti-tumor activity of surufatinib in mPDAC patients is promising. Surufatinib combined with ICI may improve the efficacy in mPDAC and provide a potential treatment option for patients, especially in the first-line setting.
Trial registration
The trial was registered at ClinicalTrials, NCT06378580